Abstract:We have previously shown that recombinant protein of kringle 1 domain of human hepatocyte growth factor (HGFK1) exhibits anti- angiogenesis activity. Here we investigated the in vivo therapeutic effect of long term expression of HGFK1 on hepatocellular carcinoma (HCC) using a recombinant adenoassociated virus carrying the HGFK1 gene (rAAV-HGFK1). We first showed that rAAV-HGFK1 infection significantly inhibited the proliferation, and the microvascular tube formation of mice microvascular endothelial cells (MEC), as well as the proliferation of the rat HCC McA-RH7777 cells but not in the non-tumor C9 cells. The in vivo efficacy of rAAV-HGFK1 was then studied in an established orthotopic Buffalo rat model of HCC. HCC was induced by injection of McA-RH7777 cells into the left lobe of the liver. Ten days after tumor cell inoculation, surgeries were performed to confirm the tumor formation, followed by injections of PBS, rAAV-EGFP (1.2×1012 v.p.) or rAAV-HGFK1 (1.2×1012 v.p.) directly into the tumor nodule (0.2×1012 v.p.), and by portal vein (1.0×1012 v.p.). We showed that rAAV-HGFK1 treatment significantly prolonged the median survival time of the HCC bearing rats from 30 days (PBS and rAAV-EGFP groups) to 49 days (rAAV-HGFK1 group). Importantly, rAAV-HGFK1 inhibited tumor growth and completely prevented liver, lung and peritoneal metastasis. No toxicity was observed when high dosage of rAAV-HGFK1 was administered in C57 mice. Furthermore, rAAV-HGFK1 appears to work by mechanisms differ from that reported for endostatin. In conclusion, this study demonstrated that rAAV-HGFK1 is potentially a promising treatment for HCC and other cancers.

Supplementary Figures 1-6 from the Kringle 1 Domain of Hepatocyte Growth Factor Has Antiangiogenic and Antitumor Cell Effects on Hepatocellular Carcinoma

Supplementary Methods, Figures 1-4 from Rho Kinase Phosphorylation Promotes Ezrin-Mediated Metastasis in Hepatocellular Carcinoma

Supplementary Figure S3 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

A Novel and Effective Hepatocyte Growth Factor Kringle 1 Domain and P53 Cocktail Viral Gene Therapy for the Treatment of Hepatocellular Carcinoma

Supplementary Figure 6 from Reversing Effect of Ring Finger Protein 43 Inhibition on Malignant Phenotypes of Human Hepatocellular Carcinoma

293. Sustained Expression of Kringle 1 Domain of Human Hepatocyte Growth Factor (HGFK1) Effectively Inhibits Angiogenesis, Growth and Metastasis of Hepatocellular Carcinoma

Supplementary Table 1 from BMP4 Administration Induces Differentiation of CD133+ Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma

Supplementary Methods, Figures 1-9, Tables 2-6 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes Β-Catenin–dependent Hepatocarcinogenesis

Hnf6 Promotes Tumor Growth In Colorectal Cancer And Enhances Liver Metastasis In Mouse Model

Supplementary Figures and Tables from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER

Supplementary Figure 1 from Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations

Supplementary Table 2 from BMP4 Administration Induces Differentiation of CD133<sup>+</sup> Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma

Supplementary Figure 6 from E2F8 Contributes to Human Hepatocellular Carcinoma Via Regulating Cell Proliferation

Supplementary Figure 3 from CXCR6 Upregulation Contributes to a Proinflammatory Tumor Microenvironment That Drives Metastasis and Poor Patient Outcomes in Hepatocellular Carcinoma

Supplementary Figure 4 from CXCR6 Upregulation Contributes to a Proinflammatory Tumor Microenvironment That Drives Metastasis and Poor Patient Outcomes in Hepatocellular Carcinoma

HGFK1 Enhances the Anti-Tumor Effects of Angiogenesis Inhibitors via Inhibition of CD90+ CSCs in Hepatocellular Carcinoma

Supplemental Figures and Legends from Multikinase Inhibitor CT-707 Targets Liver Cancer by Interrupting the Hypoxia-Activated IGF-1R–YAP Axis

Supplementary Figure 5 from Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations

Supplementary Figure 2 from Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations

Supplementary Figure 1 from A YKL-40–Neutralizing Antibody Blocks Tumor Angiogenesis and Progression: A Potential Therapeutic Agent in Cancers